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Background: Culture-independent phylogenetic analysis of 16S ribosomal RNA (rRNA) gene sequences has
emerged as an incisive method of profiling bacteria present in a specimen. Currently, multiple techniques are
available to enumerate the abundance of bacterial taxa in specimens, including the Sanger sequencing, the ‘next
generation’ pyrosequencing, microarrays, quantitative PCR, and the rapidly emerging, third generation sequencing,
and fourth generation sequencing methods. An efficient statistical tool is in urgent need for the followings tasks: (1)
to compare the agreement between these measurement platforms, (2) to select the most reliable platform(s), and
(3) to combine different platforms of complementary strengths, for a unified analysis.
Results: We present the latent variable structural equation modeling (SEM) as a novel statistical application for the
comparative analysis of measurement platforms. The latent variable SEM model treats the true (unknown) relative
frequency of a given bacterial taxon in a specimen as the latent (unobserved) variable and estimates the reliabilities
of, and similarities between, different measurement platforms, and subsequently weighs those measurements
optimally for a unified analysis of the microbiome composition. The latent variable SEM contains the repeated
measures ANOVA (both the univariate and the multivariate models) as special cases and, as a more general and
realistic modeling approach, yields superior goodness-of-fit and more reliable analysis results, as demonstrated by a
microbiome study of the human inflammatory bowel diseases.
Conclusions: Given the rapid evolution of modern biotechnologies, the measurement platform comparison,
selection and combination tasks are here to stay and to grow – and the latent variable SEM method is readily
applicable to any other biological settings, aside from the microbiome study presented here.
Keywords: Bioinformatics, Latent variable structural equation modeling, Measurement model, Reliability, Repeated
measures ANOVABackground
Complex microbial communities, like those of the hu-
man gastrointestinal (GI) tract and other environmental
specimens, have gained increased attention in recent
years, thanks to technological advances in culture-
independent methods based on the amplification of
16S rRNA genes [1,2]. The NIH Roadmap Human
Microbiome Project (HMP) has undertaken a large scale
effort to characterize 16S rRNA sequences from healthy
human subjects and from human subjects with various* Correspondence: xiaowu1@ic.sunysb.edu
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reproduction in any medium, provided the ordiseases. In the course of conducting the project, the
various sequencing centers used both ABI 3730 Sanger
sequencing and 454 FLX Titanium pyrosequencing plat-
forms to generate and release reference data from mul-
tiple body sites sampled in 300 healthy human subjects
[3,4]. Traditional phylogenetic analysis of a sample is
performed by amplifying 16S rRNA genes, cloning, and
sequencing by the Sanger method [5]. An advantage of
this method is the sufficiency of single pass Sanger se-
quencing of 900–1000 bases for classifying bacteria. Dis-
advantages include potential cloning bias [6], as well as
time and expense, which can be prohibitive for in-depth
sampling of complex microbial communities.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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a promising alternative to quantifying the micro-
biome without the limitations of cloning/Sanger seq-
uencing. For instance, a single run of the 454 Life
Sciences pyrosequencing platform can produce 1.2 million
sequences in 8 hours [7], which would require months or
years of work with the older methods. The high throughput
per run means the unit cost of NGS is only a fraction of
that for Sanger sequencing. The new technology also elimi-
nates the cloning bias by directly sequencing the 16S rRNA
genes generated by polymerase chain reaction (PCR).
Therefore, high throughput sequencing is ideal if adaptable
to meet the requirements needed for microbiome work.
However, the main limitation of high throughput sequen-
cing is read length. Reads from NGS technologies are con-
siderably shorter than those from Sanger sequencing.
Illumina’s Solexa and Applied Biosystem’s SOLiD platforms
generate reads of about 25–100 bases, while 454 sequen-
cing technology reads up to 400–500 bases per sequence.
The concern is loss of classification accuracy with shorter
sequence reads [8,9]. In addition, the bias associated with
PCR amplification is also a concern of PCR based next gen-
eration sequencing [10]. Several strategies have been tried
to maximize the information obtained from short se-
quences. One is to target hypervariable regions (HVR) that
are most informative for a specific microbiome of interest
[11,12]. As a comparison to the Sanger and the NGS
methods, quantitative PCR (qPCR) employs primers spe-
cific for particular bacterium to detect and quantify bac-
teria. Although a reliable and accurate quantification
measure for the absolute amount of 16S rRNA genes from
one specific organism [13], the accuracy of qPCR relies on
proper designs of the primers [14].
To date, few attempts have been made to systematically
compare and combine different measurement modalities
for microbiome analysis. Nossa et al. [15] surveyed broad-
range 16S rRNA primers for use in 454 pyrosequencing to
classify bacteria from the human foregut microbiome. A
length of 900 bases long reads were simulated as Sanger
sequences and treated as accurate taxonomies. The group
concluded that 347 F/803R primers (covering the 16S
rRNA V3V4 region) is the most suitable primer pair for
pyrosequencing of classification of foregut 16S rRNA
genes. Frank et al. [16] observed similar results provided
by Sanger sequencing and pyrosequencing in the human
Nasal Microbiota. One recent work has demonstrated
that the measured profile (identification and abundance)
of microbial communities depends highly on the selec-
tion of sequencing platforms – Sanger sequencing
and pyrosequencing with different target regions (V1V3,
V4V6, V7V9) yielded varying patterns for different genera
[17]. It is thus arduous to compare the accuracies of differ-
ent sequencing platforms for measuring microbiome com-
positions in an experimental approach.Here we propose an alternative analytical approach
using the latent variable structural equation modeling
(SEM) to compare and integrate microbiome measure-
ments from different measurement platforms. The latent
variable SEM treats the true bacterial composition of a
sample as the latent (unobserved) variable and estimates
the relations between, and the reliabilities of, different
measurement platforms, and if necessary, subsequently
combines them for a joint analysis with each platform
weighed by its reliability [18]. The latent variable SEM
includes the repeated measures ANOVA, both the uni-
variate and the multivariate versions, as special cases,
and is free from the rigid assumptions of the latter ap-
proaches such as weighing each platform equally in the
analysis regardless of their reliabilities and assuming
equal measurement error variances [19]. Furthermore,
as with the repeated measures ANOVA, the latent vari-
able SEM can easily incorporate covariates such as dis-
ease phenotypes and genotypes, etc. [20,21] to examine
their influences on the underlying microbiome compos-
ition/bacteria expression.
In this paper, we demonstrate the latent variable SEM
approach through a study of the microbiome in inflam-
matory bowel diseases (IBD). Our primary goal is to
identify the most reliable microbiome measurement plat-
form. A secondary goal is to examine the impact of IBD
disease phenotypes (Crohn’s Disease [CD] and ulcerative
colitis [UC]) on the enteric microbiota. The measure-
ment platforms compared in this study are: 1) ABI 3730
(Sanger) sequencing of the entire 16S rRNA gene; 2) 454
sequencing of the V1-V3 hypervariable regions; 3) 454
sequencing of the V3-V5 hypervariable region. In the
case of a single bacterial taxon, Faecalibacterium spp.,
we compared the three sequencing platforms with an
established qPCR assay.
Methods
In this section, we illustrate the general methodology for
platform comparison and combination using latent vari-
able SEM. We start with the simpler latent variable SEM
measurement model in which covariates are not in-
volved to better elucidate how latent variable SEM
gauges platform reliability and consistency. Subse-
quently, we introduce latent variable SEM with covari-
ates and describe its two special cases -- repeated
measures ANOVA in the univariate and multivariate ap-
proaches. To better assist readers with a less mathemat-
ical background in this section, each general model is
accompanied by the corresponding example from the
microbiome study on IBD.
Measurement model of latent variable SEM
In latent variable SEM, a latent variable refers to the un-
known real value such as the true frequencies of bacteria
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various measurements or indicators through a measure-
ment model. Figure 1(A) describes a measurement
model in which the latent variable ξ (for the IBD study,
the true frequency of a certain bacteria in a specimen) is
gauged through m measurements Yi(i = 1, . . .,m) (for the
IBD study, measurements from four platforms including
Sanger, two 454 windows, and qPCR). Let Y = (Y1,Y2,⋯
,Ym)
', the latent variable SEM model is a system of linear
equations: Y =Λξ + ε, where Λ = (λ1, λ2,⋯ , λm)
' is the
vector of path coefficients showing the expected number
of unit changes in the observed variables/measurements
for a one-unit change in the true level of ξ. Random er-
rors for the measurements and the latent variable itself
are denoted by ε = (ε1, ε2,⋯ , εm)
' and ζ respectively. We
further assume that all errors are normally distributed
and independent with Var(ξ) = σ2ζ , Cov(εi, ξ) = 0, Cov(εi,
εj) = 0, and Var εið Þ ¼ σ2εi (i, j = 1, . . .,m, i ≠ j). By conven-
tion, Y is usually centered about its mean and thus the
intercept terms are eliminated.
Let θ be the vector of the model parameters including
the path coefficients and the error variances and covari-
ances. For the latent SEM model illustrated in Figure 1
(A), the population covariance matrix Σ(θ) of Y implied
by the SEM model is:
Σ θð Þ ¼ E YY0ð Þ ¼ E Λ þ εð Þ Λ0 þ ε0ð Þ½  ¼ Λσ2ζΛ0 þ cov εð Þ
ð1Þ
Given the multivariate normally distribution of Y, one
can estimate the model parameters via the traditional
maximum likelihood (ML) method that will eventually re-
sult in the minimization of the following ML fit function:
FML ¼ log Σ θð Þj j þ tr SΣ1 θð Þ
  log Sj j m ð2Þ
where S is the sample covariance matrix. This in turn re-
duces to minimizing the difference between S and Σ(θ).Figure 1 Path diagram for a latent variable SEM measurement model
one latent variable; (B) The measurement model with four measurements (
relative frequency of Faecalibacterium.To fix ideas, we now illustrate the modeling and estima-
tion of the latent variable SEM in details by setting m = 3
in Figure 1(A). The SEM equations are: Y1 = λ1ξ + ε1,
Y2 = λ2ξ + ε2 and Y3 = λ3ξ + ε3, where E(Yi) = 0, E(εi) = 0,
Var Yið Þ ¼ σ2yi ; Var(ξ) = σ2ζ , Var εið Þ ¼ σ2εi ; Cov(ξ, εi) = 0
and Cov(εi, εj) = 0.
The implied covariance matrix of the model (*its
upper triangular portion is omitted in the matrix form
due to symmetry) is:
Σ θð Þ ¼ Λσ2ζΛ0 þ cov εð Þ
¼
σ2ζλ
2
1 þ σ2ε1
σ2ζλ2λ1 σ
2
ζλ
2
2 þ σ2ε2
σ2ζλ3λ1 σ
2
ζλ3λ2 σ
2
ζλ
2
3 þ σ2ε3
2
64
3
75 ð3Þ
Following convention for latent variable SEM estima-
tion, we set one of the path coefficients to 1 to assign a
scale to the latent variable [22]. This seemingly arbitrary
scale assignment has no consequence on the ensuing
model estimation because the estimated standardized
path coefficients, invariant to this arbitrary scale assign-
ment, will be reported eventually. Thereby without loss
of generality, we set λ1 ≡ 1 in Σ(θ), and subsequently, by
equating Σ(θ) and S = [Sij], the sample variance covari-
ance matrix, the maximum likelihood estimators of the
model parameters soon emerge as:
λ^2 ¼ S23S13 ; λ^3 ¼
S23
S12
; σ^ζ
2 ¼ S12S13
S23
ð4Þ
σ^ε1
2 ¼ S11  σ^ζ
2
; σ^ε2
2 ¼ S22  σ^ζ
2
; σ^ε3
2 ¼ S33  σ^ζ
2 ð5Þ
Platform reliability measure
In order to evaluate the consistency of the measurement
platforms, we adopt the concept of reliability originated
from the classical test theory by assuming a true score un-
derlies a measure [23]. In the latent SEM measurement. (A) The general model with m measurements (observed variables) for
Sanger, 454_V1V3, 454_V3V5 and qPCR) for the true (logit-transformed)
Figure 2 Path diagram for repeated measures ANOVA. In
comparison to the latent variable SEM model (Figure 1A), repeated
measures ANOVA assumes equal path coefficients for both the
multivariate and univariate analysis approaches. In addition, for the
univariate approach the measurement error variances, Var(εi), are
assumed to be equal.
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latent variable ξ and its measure Yi, is a good reliability
measure representing the percentage of variance in a
measure that is explained by the latent variable (true
score). It is appropriate under very general conditions and,
in simple cases, is equal to some of the traditional tech-
niques such as Cronbach’s alpha [22]. For the latent SEM
model illustrated in Figure 1(A), the reliability measure
for the ith platform is:
R2yi ¼ ρ2yi; ¼
cov2 yi; ð Þ
Var yið ÞVar ð Þ ¼ 1
Var εið Þ
Var yið Þ ð6Þ
The last term in the equation can be interpreted as the
proportion of variance in the measure Yi that is
explained by the latent variable ξ (See Additional file 1
Text S1 for full derivations). The estimated reliability is
also closely related to correlations between observed
measures. For example, the reliability of y2 for the sim-
ple case of one latent variable with three measurements
(Figure 1A with m= 3) is computed as:
R^
2
y2
¼ λ^22σ^ζ2σ^
2
yi
¼ S23
S13
 2
 S12S13
S23
 1
S22
¼ S12ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S11S22
p S23ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S22S33
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S11S33
p
S13
¼ r12r23
r13
ð7Þ
Here rij is the sample Pearson product moment correl-
ation coefficient between the observed variables Yi and
Yj. Similarly, we have R^y1
2 ¼ r12r13r23 and R^y3
2 ¼ r13r23r12 :
By now we have shown how to compute the R-square
from the data, and furthermore, how the R-square is re-
lated to the correlations between the observed variables.
Suppose the first two of the three measurement plat-
forms are perfectly correlated (r12 = 1) while the third
measure is poorly correlated to the first two with r13 =
r23 = 0.5. Then we have R2y1 ¼ R2y2 ¼ 1 , and R2y3 ¼ 0:25 .
That is, the first two measurements are deemed perfectly
reliable on the strength of their perfect consistency,
while the third one is considered relatively unreliable
due to its poor correlation to the other measures.
The standardized path coefficients are defined as
λ^i
¼λ^ iσ^ ζ
σ^ yi
. Together with the definition of reliability
R^yi
2¼λ^2i σ^ζ
2
σ^yi
2 ,
we can easily obtain that R^
2
yi ¼
λ^
2
i σ^
2
ζ
σ^ 2yi
¼ λ^i
 2
. Therefore,
the standardized path coefficient λ^i
 is indeed the sample
correlation between the observed measurement Yi and
the latent variable ζ. The estimated reliability of the ith
platform is equal to the squared estimated path coeffi-
cient in the latent variable SEM measurement model.Comparison to repeated measures ANOVA
The traditional approach to incorporate multiple re-
peated measures for the same underlying latent variable
is the repeated measures ANOVA. Here we show that
the latent variable SEM is a more general model – with
the repeated measures ANOVA, both the univariate and
the multivariate analysis approaches, as its special cases
(Figure 2).
The univariate repeated measures ANOVA model is:
Y = Z + ε, where w assume Y = (Y1,Y2,⋯ ,Ym)
' is cen-
tered, in analogous to SEM, thus the intercept term is
eliminated; Z is the (random) effect of subject; and ε =
(ε1, ε2,⋯ , εm)
' are independent and identically distrib-
uted random errors independent of Z. Therefore Y ~Nm
(0, Σ), where omitting the upper triangle of the matrix
by symmetry, we have
Σ ¼
σ2z þ σ2ε
σ2z σ
2
z þ σ2ε
. . . . . . . . . . . .
σ2z σ
2
z . . . σ
2
z þ σ2ε
2
664
3
775:
This particular structure of the variance covariance
matrix is called “compound symmetry”. The univariate
repeated measures ANOVA can be obtained from the
more general latent variable SEM shown in Figure 2(A)
by imposing equal measurement error variances and
equal path coefficients from the measurements to the la-
tent variable. That is, λi ≡ 1 and σ2εi ≡ σ
2
ε (i = 1, 2, . . .m).
The multivariate approach for repeated measures
ANOVA allows different measurement error variances
but still imposes equal weights to path coefficients from
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(i = 1, 2, . . .m) as shown in Figure 2. The resulting vari-
ance covariance matrix Σ for Y is:
σ2z þ σ2ε1
σ2z σ
2
z þ σ2ε2
. . . . . . . . . . . .
σ2z σ
2
z . . . σ
2
z þ σ2εm
2
664
3
775:
In summary, the repeated measures ANOVA models,
both the univariate and the multivariate approaches, are
special cases of latent variable SEM with constraints on
the error variances and path coefficients. The general la-
tent variable SEM is a more realistic, flexible and better-
fitting model to evaluate the latent variable with several
measurements, especially when the reliability of each
measurement is unclear and the assumption of equal
error variances is questionable. This general principle is
fully illustrated in the ensuing example of a microbiome
study where we compared the latent SEM measurement
model with both repeated measures ANOVA models.
Latent variable SEM with covariates
While one advantage of the latent variable SEM is the
ability to simultaneously incorporate multiple measures
for the same underlying latent variable in a measure-
ment model as shown in the previous section, SEM also
can integrate multiple covariates for a latent variable in
the same model. In the ensuing example of IBD, we sim-
ultaneously examine the influence of disease phenotypes
and genotypes on the underlying bacterial ensemble
while incorporating measures from multiple platformsFigure 3 Path diagram for a latent variable SEM with covariates. (A) A
variable ξ. (B) The model with four measurements (Sanger, 454_V1V3, 454_
CD (= 1 for subjects with Crohn’s disease, and 0 otherwise), and UC (= 1 fo
(logit-transformed) relative frequency of Faecalibacterium.(e.g., Sanger sequencing, 454 pyrosequencing, and
qPCR). As illustrated in Figure 3(A), by integrating k co-
variates that might influence the latent variable, the path
diagram of the latent variable SEM measurement model
illustrated in Figure 1(A) acquires an additional layer.
The SEM model for Figure 3(A) is:
Y ¼ Λ þ ε
 ¼ Γ0Xþ ζ ð8Þ
Here, Y is a vector of measurement variables for the
latent variable ξ, and X is a vector of independent vari-
ables (covariates) affecting the latent variable ξ. Both Y
and X have been centered about their means per SEM
convention. In addition to the notation in the measure-
ment model, we have Γ = (γ1, γ2,⋯ , γk)
' representing the
vector of path coefficients from the covariates to the la-
tent variable. The estimation procedure is very similar to
the measurement model as well. We can break the co-
variance matrix Σ(θ) into a block matrix as follows:
Σ θð Þ ¼ Λ Γ
0 cov Xð ÞΓþ σ2ζ
 
Λ0 þ cov εð Þ ΛΓ0 cov Xð Þ
cov Xð ÞΓΛ0 cov Xð Þ
" #
:
ð9Þ
Thus the parameters can be estimated through minim-
izing the ML fitting function, or equivalently, by equat-
ing Σ(θ) and S, the sample covariance matrix for both
X and Y.
Nonparametric analysis of latent variable SEM
In the above, we presented the analysis of latent variable
SEM based on the most widely used maximum likelihoodgeneral model with m measurements and k covariates for one latent
V3V5 and qPCR) and two covariates -- two binary disease indicators:
r subjects with ulcerative colitis, and 0 otherwise) for the true/latent
Table 1 Pearson correlations among four different
measurement modalities for the logit transformed
relative frequency of Faecalibacterium (N = 142)
Sanger 454_V1V3
(p value)
454_V3V5
(p value)
qPCR
(p value)
Sanger 1 0.828 (<.001) 0.866 (<.001) 0.642 (<.001)
454_V1V3 1 0.887 (<.001) 0.624 (<.001)
454_V3V5 1 0.610 (<.001)
qPCR 1
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assumptions. In practice, SEM with continuous variable,
including ordinal variables of five categories or more will
not have severe problems with non-normality. When the
normality assumption is not attainable, one can not dir-
ectly employ the hypothesis test or confidence interval re-
sults. One can employ bootstrap resampling procedures to
perform nonparametric significance tests and to construct
nonparametric confidence intervals [22,24]. Here we have
adopted Efron’s non-parametric bootstrap by re-sampling
from the original data with replacement and subsequently
obtain the nonparametric bootstrap estimation [25].
In order to fully analyze the following application ex-
ample on IBD and microbiome, we developed a modified
boot.sem function by adapting the boot.sem function
from the R package SEM (version 0.9-21) to estimate
platform reliability and the standardized latent variable
SEM path coefficients and other parameters whenever
the normality assumption is not attainable. Our modified
boot.sem function is available for free download at
http://www.ams.sunysb.edu/~zhu/wei/SEM.html. As an
example, the 95% bootstrap confidence intervals of the
reliabilities based on the 2.5th and the 97.5th percentiles
of the resampled data are shown in the following
section.
Results and discussion
Data and model descriptions
Inflammatory bowel diseases (IBD), including Crohn’s
disease (CD) and ulcerative colitis (UC), are chronic in-
flammatory conditions of the small intestine and/or the
colon. The IBD study reported here includes 39 ileal CD
patients, 50 UC patients, and 53 non-IBD control sub-
jects, specimens from which were subjected to
microbiome analysis. The abundance of the bacterial
genus Faecalibacterium (a member of the Clostridium
Group IV of the phylum Firmicutes) from disease un-
affected ileal samples collected from the proximal mar-
gin of resected ileum of each subject was determined
from four measurement modalities: Sanger sequencing,
454 pyrosequencing of two hypervariable regions of the
16S rRNA gene (V1V3 and V3V5), and quantitative PCR
(qPCR) [26]. Assembled Sanger sequences were depos-
ited in GenBank accession HQ739096-HQ821395. 454
V1V3 and V3V5 sequences were deposited in the Se-
quence Read Archive accession SRX021348-SRX021368,
SRX037800-SRX037802. The qPCR assay was performed
for Faecalibacterium prausnitzii and total bacteria using
established primers [27]. F. prausnitzii is a predominant
species found in the human gastrointestinal microbiome
that has been implicated in CD [28,29]. For each sequen-
cing platform, the relative frequency of this bacterial
taxon was calculated and then subjected to the empirical
logit transformation as described in Li and others [26].The qPCR data (dCT) were converted as qPCR = logit
(2dCT) so that all four measurements were subjected to
the same transformation. The IBD phenotypes (CD and
UC) are incorporated as two covariates into the SEM
model for an association analysis as well. Path diagrams
for the latent variable SEM measurement, and covariate
models for Faecalibacterium are shown in Figure 1(B)
and Figure 3(B) respectively.
Consistency and reliability of different measurement
modalities
Table 1 shows the Pearson correlation among the four
measurement modalities for the logit transformed relative
frequency of Faecalibacterium. The V3V5 pyrosequencing
window is the best correlated among all modalities. In
contrast, the qPCR data have relatively low correlations
with all three sequencing measures, suggesting that the
target of qPCR, F. prausnitzii, might not represent the full
faecalibacterial diversity in the sample set. Therefore, al-
though qPCR is often treated as the gold standard for the
quantification of nucleotide sequences, it may be limited
by its high dependency on the accurate specification of
primers of targets.
The reliabilities of these measurement modalities, as
estimated by the squared correlation coefficients be-
tween measurements and the latent variable, are shown
in the Table 2. Again, the V3V5 pyrosequencing window
was found to be the most reliable with a reliability score
of 0.912, and a correlation of 0.955 to the true under-
lying Faecalibacterium expression.
Because the reliability measure calculated in this
model is closely related to the correlations among
measurement modalities, and because the two 454
pyrosequencing windows feature the highest correlation
(r = 0.887), we also evaluated a three-modality measure-
ment model that dropped the 454 V1V3 data (the less
reliable pyrosequencing window). In this independent
platform comparison, Sanger sequencing emerged as the
most reliable platform among the three modalities with
an estimated reliability of 0.911 and an estimated correl-
ation of 0.955 with the underlying Faecalibacterium fre-
quency (Table 3, upper half ). Result is similar, with
Sanger sequencing being the most reliable measure-
ment, if an alternative three-modality comparison was
Table 2 Reliability of each measurement platform in the
four-modality latent variable SEM measurement model,
and its correlation to the latent variable (true relative
frequency of Faecalibacterium)
Four- modality measurement model
Sanger 454_V1V3 454_V3V5 qPCR
Reliability 0.819 0.857 0.912 0.441
(95% CI) (0.689, 0.907) (0.774, 0.917) (0.865, 0.963) (0.303, 0.553)
Correlation to the
latent variable
0.905 0.926 0.955 0.664
(95% CI) (0.830, 0.952) (0.880, 0.958) (0.930, 0.981) (0.550, 0.744)
The 95 % confidence intervals are obtained using bootstrap resampling with
100 replications [24].
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lower half ).
Path diagrams for the measurement models with the
estimated standardized path coefficients are shown in
Figure 4. As demonstrated above, the standardized path
coefficients are indeed the correlations between each
measurement and the latent variable.
In addition to Faecalibacterium, similar analyses have
been performed for several other bacterial taxa which are
potentially associated with IBD (with the latent variable
SEM results shown in Table 4 below and the correspond-
ing Pearson correlations between the observed variables
listed in Additional file 1: Table S1). With the three meas-
urement platforms (Sanger, 454_V1V3 and 454_V3V5)
available for these bacterial groups (the qPCR was not
performed for these groups, unfortunately), the 454_V3V5
window is shown to be a better measurement platform
for Proteobacteria, Actinobacteria, Bacteroidetes and
Firmicutes/Bacilli, while the 454_V1V3 window is found
to be more reliable for Firmicutes/Clostridia/Clostridiales/
LachnoIV. This observation is consistent with, and thusTable 3 Reliability of each measurement platform in the
three-modality latent variable SEM measurement model,
and its correlation to the latent variable (true relative
frequency of Faecalibacterium)
Three- modality measurement model
Sanger 454_V3V5 qPCR
Reliability 0.911 0.822 0.452
(95% CI) (0.775, 1.000) (0.720, 0.912) (0.323, 0.610)
Correlation to the
latent variable
0.955 0.907 0.672
(95% CI) (0.880, 1.000) (0.849, 0.955) (0.568, 0.781)
Sanger 454_V1V3 qPCR
Reliability 0.851 0.806 0.483
(95% CI) (0.671, 1.000) (0.645, 0.905) (0.350, 0.648)
Correlation to the
latent variable
0.922 0.898 0.696
(95% CI) (0.819, 1.000) (0.803, 0.951) (0.592, 0.805)
The 95% confidence intervals are obtained using bootstrap resampling with
100 replications. Two 3-modality models are shown with Sanger, qPCR, and
454_V3V5 in the first model, and 454_V1V3 in the second model.
Figure 4 The estimated (A) four-modality (B) three-modality
(Sanger, 454_V3V5, qPCR) and (C) three-modality (Sanger,
454_V1V3, qPCR) latent variable SEM measurement models for
a study of the inflammatory bowel diseases.further confirmed the point made by the joint panel of
human microbiome project in that different 454
pyrosequencing windows may be optimal for different
bacterial taxa [4].
Comparison to repeated measures ANOVA
The model goodness-of-fit indices for the four-modality
latent variable SEM measurement models for
Faecalibacterium are listed in Table 5, and compared to
those for the repeated measures ANOVA in both the
univariate and the multivariate analysis approaches.
SEM relies on several statistical tests to determine the
adequacy of model fit to the data. The chi-square test in-
dicates the amount of difference between the expected
Table 4 Reliability for more bacterial taxa in the three-
modality latent variable SEM measurement model
(Sanger, 454_V1V3 and 454_V3V5), and its correlation to
the latent variable
Three-measurement modality model
Sanger 454_V1V3 454_V3V5
(A) Proteobacteria
Reliability 0.657 0.641 0.974
(95% CI) (0.524, 0.793) (0.529, 0.724) (0.878, 1.000)
Correlation to the
latent variable
0.811 0.801 0.987
(95% CI) (0.724, 0.891) (0.727, 0.851) (0.937, 1.000)
(B) Firmicutes/Clostridia/
Clostridiales/LachnoIV
Reliability 0.685 0.923 0.793
(95% CI) (0.582, 0.804) (0.837, 1.000) (0.688, 0.903)
Correlation to the
latent variable
0.827 0.961 0.890
(95% CI) (0.763, 0.897) (0.915, 1.000) (0.829, 0.950)
(C) Actinobacteria
Reliability 0.582 0.854 0.882
(95% CI) (0.424, 0.700) (0.743, 0.942) (0.765, 0.976)
Correlation to the
latent variable
0.763 0.924 0.939
(95% CI) (0.652, 0.837) (0.862, 0.970) (0.875, 0.988)
(D) Bacteroidetes
Reliability 0.684 0.828 0.980
(95% CI) (0.323, 0.922) (0.652, 1.000) (0.941, 1.000)
Correlation to the
latent variable
0.827 0.910 0.990
(95% CI) (0.569, 0.960) (0.808, 1.000) (0.970, 1.000)
(E) Firmicutes/Bacilli
Reliability 0.698 0.953 0.959
(95% CI) (0.553, 0.797) (0.888, 1.000) (0.913, 0.995)
Correlation to the
latent variable
0.835 0.976 0.979
(95% CI) (0.744, 0.893) (0.942, 1.000) (0.956, 0.998)
The 95% confidence intervals are obtained using bootstrap resampling with
100 replications.
Table 5 Model goodness-of-fit comparison between latent va
Faecalibacterium based on four measurements (Sanger, 454 py
MODEL MODEL CONSTRAINT
A: Latent variable SEM set only λ1 = 1
B: Equivalent to repeated measures
ANOVA (multivariate approach)
set all indicator path coefficient λi
C: Equivalent to repeated measures
ANOVA (univariate approach)
set all indicator path coefficient λi
variances to be equal, var (εi) ≡ σ
2
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indicate little difference between expected and observed
covariance matrices). The root mean square error of ap-
proximation (RMSEA), which is related to the residuals
in the SEM model, ranges from 0 to 1 with a smaller
RMSEA value indicating better model fit. Acceptable
model fit is indicated by an RMSEA value of 0.06 or less
[30]. The Comparative Fit Index (CFI) is equal to the
discrepancy function adjusted for the sample size. That
is, CFI = 1 – d(proposed model)/d(null model), where d is equal
to the corresponding chi-square minus the degrees of
freedom of the model. The CFI ranges from 0 to 1 with
a larger value indicating better model fit. Acceptable
model fit is indicated by a CFI value of 0.90 or greater
[30]. As shown in Table 5, the latent variable SEM
(model A) has significantly better Chi-square goodness-
of fit index (χ2 = 5.089, p = 0.079) than model B and C
representing the repeated measures ANOVA in the
multivariate and univariate approaches respectively.
Model A also has relatively better RMSEA index than
model B and C. For the CFI criterion, only model A pro-
vides good fit with a values above 0.9. In summary, the
(general) latent variable SEM is the only model that
fits the data well as neither of the repeated measures
ANOVA models is satisfactory.
Estimation of the latent variable SEM model with IBD
phenotypes
In this section, we examine the impact of two IBD phe-
notypes, Crohn’s Disease (CD) and ulcerative colitis
(UC), on the relative frequency of Faecalibacterium via
latent variable SEM, simultaneously utilizing measure-
ments of the given genus from either all four modalities,
or only three distinct modalities (minus the V1V3 win-
dow of the 454 pyrosequencing). CD patients are found
to have significantly lower relative abundance of
Faecalibacterium (p < .001) in both four- and three-
modality latent variable SEM analysis. While UC pa-
tients were confirmed to have significant lower average
concentration of Faecalibacterium in the three-modalityriable SEM and repeated measures ANOVA approach of
rosequencing V1V3, 454 pyrosequencing V3V5 and qPCR)
GOODNESS-OF-FIT
Chi-square 5.089 (df = 2) Pr > χ2: 0.079
RMSEA 0.105
CFI 0.994
≡ 1 (i = 1, 2, 3, 4) Chi-square 129.955 (df = 5) Pr > χ2: < .001
RMSEA 0.421
CFI 0.750
≡ 1; set all indicator error
(i = 1, 2, 3, 4)
Chi-square 172.068 (df = 8) Pr > χ2: < .001
RMSEA 0.381
CFI 0.671
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the four-modality model (p = 0.086) (Figure 5). The dif-
ference may lie in the decrease of model parameters for
the three-modality model that renders it more powerful
to detect the underlying difference than the four-
modality model. In accordance to previous reports that
low relative frequency of F. prausnitzii has been found
in ileal CD patients and it has been associated with an
increased risk of ileocolonoscopic recurrence of ileal
CD [31].
The estimated values of path coefficients in the associ-
ation study with IBD phenotype are interpreted as fol-
lows. Take the three- modality covariate latent variable
SEM for example (Figure 5). The relation between the
estimated logit transformed true relative frequency (π) of
Faecalibacterium (the latent variable ξ) and the pheno-
types CD and UC is interpreted as follows:
^ ¼ log π^
1 π^
 
¼ 0:592 CD 0:164 UC
This translates to:
π^ CD;UCð Þ ¼ exp 0:592 CD 0:164 UCð Þ
1þ exp 0:592 CD 0:164 UCð Þ
Therefore in comparison to the control subjects, CD
patients are found have an average 14.4% less
(p < .001) Faecalibacterium as the following simple cal-
culation shows:
π^ CD ¼ 1;UC ¼ 0ð Þ  π^ CD ¼ 0;UC ¼ 0ð Þ ¼ 0:144
Similarly, UC patients are found to have 4.1 % less
Faecalibacterium than the control subjects (p = 0.048)
because π^ CD ¼ 0;UC ¼ 1ð Þ  π^ CD ¼ 0;UC ¼ 0ð Þ ¼
0:041.
The mean differences of the logit-transformed relative
frequency of Faecalibacterium among CD, UC and con-
trol are shown in Figure 6, by Sanger, 454 V1V3, 454
V3V5 and qPCR, respectively. In this case, the trend of
decreased relative frequency of Faecalibacterium from
controls to UC and to CD, appears in agreement amongFigure 5 The estimated (A) four- and (B) three-modality latent variab
phenotypes with their path coefficients and the corresponding p-valuall four measurements. Pairwise comparisons on the
relative frequency of Faecalibacterium between UC, CD
and control within each measurement platform using
Tukey’s studentized range test revealed significant differ-
ence between CD and controls, while the difference be-
tween UC and controls remains insignificant, for all four
measurements – consistent to the latent variable SEM
results shown in Figure 5(B).
Conclusions
In this work, we introduced the latent variable SEM as a
versatile and effective analytical tool for measurement
platform comparison and combination. While traditional
SEM relied on the normality assumption for its paramet-
ric based inference, thanks to contemporary nonpara-
metric techniques such as the bootstrap resampling
method [22,24] and the rapid advancement of modern
computers, one can readily perform non-parametric ana-
lysis of latent variable SEM when the data are not nor-
mal as we have shown in the analysis of a microbiome
study of the human inflammatory bowel diseases.
In the study of the gastrointestinal microbiome, we
demonstrated that latent variable SEM can provide a ro-
bust means of integrating datasets derived from different
experimental platforms. Moreover, it can gauge effectively
the relative merits of different measurement platforms, in
this example, Sanger sequencing, 454 pyrosequencing
with two different target regions/windows, and qPCR.
Joint panel studies [4] have shown that different 454
pyrosequencing windows may be optimal for different
bacterial taxa. Their observations have been confirmed by
our own analysis using the latent variable SEM measure-
ment models (Table 4) based on the given IBD study –
where the 454_V3V5 window are shown to be a better
measurement platform for Proteobacteria, Actinobacteria,
Bacteroidetes and Firmicutes/Bacilli in addition to the
Faecalibacterium, while the 454_V1V3 window is found
more reliable for Firmicutes/Clostridia/ Clostridiales/
LachnoIV.
The joint study panel has also recommended sequen-
cing microbiome with two 454 pyrosequencing windowsle SEM models examining the effect of two covariates: CD and UC
es (in parentheses).
Figure 6 Comparison of logit-transformed relative frequency of Faecalibacterium among CD, UC and control by four measurements
(qPCR, 454_V1V3, 454_V3V5 and Sanger sequencing) respectively. Mean and standard error are shown on each bar. Pairwise comparisons
between UC, CD and control within each measurement platform are performed using Tukey’s studentized range test and significantly different
pairs at the familywise error rate of 0.05 are labeled with the asterisk (*) representing significantly different pairs.
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http://www.biomedcentral.com/1471-2105/14/79such as V1V3 and V3V5 – which we can readily com-
bine using the latent variable SEM for a unified joint
analysis. Nevertheless, more works need to be done for a
thorough treatment of the platform comparison prob-
lem. For example, we have yet to examine the rare taxa
issue. Given that data from rare taxa will feature near
zero counts and artificially low or suspiciously high vari-
ances, a robust version of the current latent SEM
method needs to be developed for the occasion. We def-
initely expect to submit a follow-up paper on this issue.
To our knowledge, this is the first application of latent
variable SEM to the study of human microbiome, and for
modern sequencing platform comparison and combin-
ation. Since human gastrointestinal microbial communities
are typically complex and difficult to study in situ, multiple
experimental/measurement modalities are required to pro-
vide a deep description of the dynamic microbe-microbe
and microbe-host interactions in the gut. Given the rapid
evolution of modern sequencing technologies, with the
debut Sanger sequencing quickly followed by the
higher throughput ‘next generation sequencing’ (a.k.a.
pyrosequencing) with shorter sequence reads, and with a
variety of third and fourth generations sequencing tech-
nologies already on the horizon, the platform comparison
and combination task is becoming increasingly critical.Additional file
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